Previous 10 | Next 10 |
2024-01-22 08:37:55 ET Rail Vision ( RVSN ) +96% Successfully Secures Approval and Certifications and for EU Railway Standards. Nustar Energy ( NS ) +23% to buy NuStar in all-stock deal valued at $7.3B. MSP Recovery ( LIFW ) +23% . North...
2023-12-08 08:20:25 ET MBIA ( MBI ) +66% declares extraordinary cash dividend; shares up premarket Volato Group ( SOAR ) +51% . FLJ Group ( FLJ ) +23% . MicroAlgo ( MLGO ) +15% . Eneti ( NETI ) +10% Announce Ext...
2023-11-27 10:34:03 ET More on Tharimmune, Inc. Financial information for Tharimmune, Inc. For further details see: Tharimmune stock rockets 46% on positive Phase 1 data for PBC drug
2023-11-27 07:30:00 ET Summary Genfit is close to possible approval for its drug team-up with Ipsen, with positive Phase 3 readouts having been achieved. The company focuses on developing therapeutic products for liver diseases, currently with a primary focus on Primary Biliary Ch...
2023-11-19 09:52:24 ET Summary Today, we revisit CymaBay Therapeutics, a clinical stage biopharma company focused on developing therapies for liver and chronic diseases. The company's primary product candidate, seladelpar, has shown positive results in treating primary biliary cho...
2023-11-13 20:41:53 ET More on Genfit Genfit GAAP EPS of -€0.42, revenue of €15.37M Seeking Alpha’s Quant Rating on Genfit Historical earnings data for Genfit Financial information for Genfit For further details see: Genfit st...
2023-11-13 18:01:34 ET Gainers: Theseus Pharmaceuticals ( THRX ) +35% . GENFIT ( GNFT ) +15% . Lifeway Foods ( LWAY ) +9% . Digital World Acquisition ( DWACW ) +8% . Digital World Acquisition ( DWAC ) +5% . Lose...
2023-09-20 16:21:53 ET More on Genfit Seeking Alpha’s Quant Rating on Genfit Historical earnings data for Genfit Financial information for Genfit Genfit gains as Phase 3 trial for liver disease candidate succeeds (update) For further details se...
2023-09-10 06:05:05 ET Summary Positive results achieved in phase 3 RESPONSE study, which used seladelpar for the treatment of patients with primary biliary cholangitis. Positive results of the phase 3 RESPONSE study leads to additional data at an upcoming medical meeting and poss...
2023-09-07 07:56:40 ET More on CymaBay Seeking Alpha’s Quant Rating on CymaBay Therapeutics Historical earnings data for CymaBay Therapeutics Financial information for CymaBay Therapeutics CymaBay Therapeutics, Inc. ( CBAY ) Q2 2023 Earnings Call...
News, Short Squeeze, Breakout and More Instantly...
2024-06-11 09:30:02 ET H.C. Wainwright analyst issues BUY recommendation for GNFT on June 11, 2024 07:43AM ET. The previous analyst recommendation was Buy. GNFT was trading at $5.535 at issue of the analyst recommendation. Historical Analyst Recommendations Latest ...
Lakeland Industries Inc. (LAKE) is expected to report $0.3 for Q4 2024 Sekisui House Ltd. ADR (SKHSY) is expected to report for Q4 2024 Hingham Institution for Savings (HIFS) is expected to report for Q1 2024 GENFIT S.A. (GNFT) is expected to report for Q4 2023 Jewett-Cameron Trad...
Seal Rock Therapeutics Announces Out-Licensing Agreement with GENFIT for Development of Injectable Formulation of SRT-015 for Acute-on-Chronic Liver Disease (ACLF) PR Newswire Seal Rock eligible to receive payments up to €100 million, including regulatory, clinical,...